Nordic Nanovector provides update on LYMRIT 37-05 Phase 1 DLBCL trial
Oslo, Norway, 12 December 2019 Nordic Nanovector ASA (OSE: NANO) reports an update on its LYMRIT 37-05 Phase 1 trial of Betalutin® in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) who are not eligible for autologous stem cell transplantation (SCT). DLBCL is an aggressive form of non-Hodgkin's lymphoma (NHL) and accounts for up to 43% of all cases, making it the most common type of NHL. This open-label, dose-escalation safety trial is designed to assess the safety, tolerability, pharmacokinetic profile and preliminary anti-tumour activity of Betalutin® in